Amgen Ventures invests in Ember LifeSciences in deal boosting Series A to $27 million

Amgen Inc.

Amgen Inc.

AMGN

0.00
  • Amgen Ventures made a strategic equity investment in Ember LifeSciences, lifting the cold-chain technology company’s Series A funding to USD 27 million.
  • TDF Ventures also invested; financial terms were not disclosed.
  • Funding supports Ember’s commercial rollout of its reusable, modular cold-chain shipping platform with real-time monitoring and cloud-based tracking.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270900PR_NEWS_USPR_____LA68517) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.